【康方生物爱达罗治疗中重度斑块状银屑病适应症获批上市】 2025年4月18日,康方生物宣布,公司独立自主研发的爱达罗®获得国家药品监督管理局批准上市,适用于中重度斑块状银屑病成人患者的治疗。依若奇单抗是第一个且唯一获批上市的IL-12/IL-23“双靶向”单克隆抗体新药,是康方生物自身免疫性疾病领域首个获批上市的一类新药,也是继伊努西单抗之后公司第二个获批上市的非肿瘤新药。

金融界
18 Apr
2025年4月18日,康方生物宣布,公司独立自主研发的爱达罗®获得国家药品监督管理局批准上市,适用于中重度斑块状银屑病成人患者的治疗。依若奇单抗是第一个且唯一获批上市的IL-12/IL-23“双靶向”单克隆抗体新药,是康方生物自身免疫性疾病领域首个获批上市的一类新药,也是继伊努西单抗之后公司第二个获批上市的非肿瘤新药。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10